Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study

Table 5 Evaluation of association between statin exposure and lung cancer histology

	Multivariable Regression
	HR	95% CI LL	95%CI UL	p value
NSCLC
Time-Dependent Statin Exposure^a	0.83	0.70	0.99	0.0349
Recency-Weighted Duration of Use^b	0.83	0.75	0.92	0.0004
SCLC
Time-Dependent Statin Exposure	1.18	0.77	1.80	0.4542
Recency-Weighted Duration of Use	1.04	0.82	1.32	0.7561

HR hazard ratio, CI confidence interval, LL lower limit, UL upper limit, NSCLC non-small cell lung cancer, SCLC small cell lung cancer. ^a This is the reference-case for the analysis. ^b The recency weighted duration of use exposure metric is presented because it was selected as the best model based on AIC values (an a priori criterion)

ISSN: 1465-993X